Core Viewpoint - The Hong Kong biopharmaceutical sector experienced a significant decline, with major companies reporting substantial drops in stock prices, indicating a bearish trend in the market [1]. Group 1: Stock Performance - Innovent Biologics (099660) saw a decline of 11.54%, with a latest price of 16.640 and a market capitalization of 293.36 billion, despite a year-to-date increase of 171.90% [2]. - Rongchang Biologics (09995) dropped by 9.20%, priced at 108.600, with a total market value of 612.08 billion, and a remarkable year-to-date increase of 654.17% [2]. - Kelun-Biotech (06990) fell by 7.71%, with a latest price of 533.000 and a market cap of 1,242.88 billion, while still showing a year-to-date increase of 226.39% [2]. - Tigermed (03347) decreased by 6.86%, priced at 43.960, with a market capitalization of 378.51 billion and a year-to-date increase of 44.25% [2]. - WuXi AppTec (02268) experienced a decline of 6.22%, with a latest price of 77.650 and a market cap of 954.09 billion, maintaining a year-to-date increase of 153.34% [2]. - CanSino Biologics (09926) dropped by 5.15%, priced at 134.500, with a market capitalization of 1,238.94 billion, and a year-to-date increase of 121.58% [2]. - Other companies like Junshi Biosciences (01877) and BeiGene (06160) also reported declines, with respective decreases of 3.16% and 2.48% [2].

Group 1 - The Hong Kong stock market showed positive performance during the National Day holiday, with the Hang Seng Index rising by 0.4%, the Hang Seng Tech Index increasing by 1.3%, and the Hang Seng China Enterprises Index up by 0.2% from October 1 to October 6, 2025. The gains were primarily driven by October 2 [2][5][6] - The MSCI Hong Kong Growth Index fell by 0.3%, while the MSCI Hong Kong Value Index decreased by 0.1% during the same period [5][6] - Key sectors that performed well included steel (+5.60%), electronics (+3.90%), non-ferrous metals (+3.78%), and power equipment and new energy (+3.43%), while agriculture, real estate, food and beverage, and consumer services sectors lagged [5][6] Group 2 - Gold and AI narratives emerged as leading themes during the holiday period, with the U.S. government shutdown impacting market sentiment and driving up COMEX gold and silver prices, benefiting the non-ferrous metals sector in Hong Kong [6][7] - The release of the experimental version DeepSeek-V3.2-Exp on September 29, 2025, contributed to the growth of the AI industry chain in China, leading to significant gains for semiconductor leaders and major internet companies in the Hong Kong market [6][7] Group 3 - As of October 6, 2025, the AH premium rate stood at 129.6%, close to the historical average of 127.1% since 2009, showing a significant decline from over 140% in May [7] - The VHSI index remained stable around 21, indicating a steady market environment, while the average daily trading volume in Hong Kong stocks showed an upward trend [7][8] - Short-term liquidity tightened slightly during the holiday period, as indicated by the 3-month HIBOR and overnight HIBOR rates [7][8] Group 4 - Future prospects for the Hong Kong stock market suggest potential for new highs, contingent on three assumptions: continued inflow of southbound capital, the performance of AI technology and new consumption sectors, and the transmission of monetary policy from broad money to broad credit [8] - The report emphasizes that if these conditions are met, the Hong Kong market could see further upward momentum, supported by a rebound in related industries [8]

FF301 呈交日期: 2025年10月6日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02268 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 10,000,000,000 | USD | 0.00005 | USD | | 500,000 | | 增加 / 減少 (-) | | | | | | USD | | | | 本月底結存 | | | 10,000,000,000 | USD | 0.00005 | USD | | 500,000 | 本月底法定/註冊股本總額： USD 500,000 第 1 頁 共 11 頁 v 1.1.1 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年9月30日 狀態: 新提交 致：香港 ...

Core Insights - The report highlights an increasing investment trend from both domestic and foreign investors in service-oriented companies and innovative pharmaceutical firms, particularly in the context of anticipated interest rate cuts in Q4 [1][2] - The Hang Seng Healthcare Index rose by 2.2% this week, underperforming the broader market, with CXO, biopharmaceuticals, and traditional Chinese medicine sectors showing better performance [1] Investment Insights - The upcoming ESMO conference in mid-October is expected to provide significant data releases from companies such as Kangfang Biotech, Kelun-Biotech, and Rongchang Biotech, which are recommended for close monitoring [2] - With an increase in industry catalysts starting in October, the market is anticipated to rebound, focusing on the following segments: 1. Innovative drugs: Companies like 3SBio and Eucure Biopharma have rich short-term catalysts, and their valuations do not yet reflect the value of core blockbuster products. Companies like Sinopharm and Legend Biotech are considered undervalued with clear long-term growth logic [2] 2. CXO: Leading companies in this segment are expected to benefit from high downstream demand and marginal improvements in financing conditions, such as WuXi AppTec [2]

Core Viewpoint - The Hang Seng Healthcare Index increased by 2.2% last week, underperforming the broader market, with the CXO, biopharmaceutical, and traditional Chinese medicine sectors showing better performance [1] Group 1: Market Trends - Domestic investors have been increasing their holdings through the Hong Kong Stock Connect since September, while foreign investors' holdings have slightly decreased since mid-year, although both continue to focus on innovative drug companies [1] - Both domestic and foreign investors have increased their positions in service-related stocks, particularly those that may benefit from interest rate cuts, such as CXO companies [1] Group 2: Upcoming Events - The ESMO conference is scheduled for mid to late October, and the report suggests focusing on companies like CanSino Biologics (09926), Kelun-Biotech (06990), and Rongchang Biologics (09995), which are expected to release significant data [1] Group 3: Investment Recommendations - The report recommends attention to the following sectors: 1) Innovative drugs: Companies like 3SBio (01530) and Eucure Biopharma-B (06996) have abundant short-term catalysts and their valuations do not yet reflect the value of core products; companies like Ascletis Pharma (02096), Hutchison China MediTech (00013), and Legend Biotech are significantly undervalued with clear long-term growth logic [1] 2) CXO: Leaders in this segment, such as WuXi AppTec (02268), are expected to benefit from high downstream demand and improving financing conditions [1]

智通财经APP获悉，2025年10月6日，港股上市公司投资日志如下： | 类别 | 公司 | | --- | --- | | | 挚达科技 | | | (招股中) | | 新股活动 | 金叶国际集团 | | | (招股中) | | | 中创新航 | | | 新爱德集团 | | | 创业集团控股 | | | 药明合联 | | 股东大会召开日 | 雅生活服务 | | | 弥明生活百货 | | | 栢能集团 | | | 新华通讯频媒 | | | 慕诗国际 | | 停复牌 | （复牌） | | | 万洲国际 | | | （除净日） | | | 广南(集团) | | | （除净日） | | | 亚洲金融 | | | （派息日） | | | 快手-W | | | （派息日） | | | 永泰地产 | | | （派息日） | | | BOSS直聘-W | | | （除净日） | | | 业聚医疗 | | 分红派息 | （派息日） | | | 思科-T | | | （除净日） | | | IBI GROUP HLDGS | | | （派息日） | | | 汉国置业 | | | （派息日） | | | 亿都(国际控股) | | ...

Core Insights - The report from CMB International highlights the release of the first batch of innovative pharmaceutical technology medical insurance payment incentive catalog by Zhejiang Province, which is expected to alleviate the challenges of innovative drugs entering hospitals [1] - Despite the Trump administration's announcement of a 100% tariff on imported innovative drugs, the overall impact on China's pharmaceutical industry chain is considered manageable, with a recommendation to monitor subsequent developments [1] - The upcoming ESMO conference in mid to late October is noted as a key event, with a focus on companies such as CanSino Biologics (09926), Kelun-Biotech (06990), and Rongchang Biologics (688331.SH) that are expected to release significant data [1] Industry Summary - The Hong Kong pharmaceutical sector has shown relatively flat performance in September, but with increasing industry catalysts such as academic conferences and favorable policy implementations in October, a market rebound is anticipated [1] - The report recommends focusing on specific segments: 1) Innovative drugs: Companies like 3SBio (01530) and Eucure Biopharma-B (06996) have rich short-term catalysts and their valuations do not yet reflect the core value of major products; companies like Ascletis Pharma (02096), Hutchison China MediTech (00013), and Legend Biotech are considered significantly undervalued with clear long-term growth logic [1] 2) CXO: Leaders in this segment, such as WuXi AppTec (02268), are expected to benefit from high downstream demand and marginal recovery in financing [1]

Market Overview - The Hong Kong stock market has seen significant gains, with the Hang Seng Index rising by 1.61% and the Tech Index increasing by 3.36%, marking a four-year high for both indices [1][3] - The overall market sentiment indicates a strong upward trend rather than speculative trading, as evidenced by the broad-based rally across sectors [1][3] Technology Sector - Tech stocks have shown robust performance, with Kuaishou leading the charge with an over 8% increase, followed by Baidu at 4%, and other major players like JD, Xiaomi, and Alibaba also rising by around 3% [3] - Semiconductor stocks, particularly SMIC, surged over 12%, driven by increasing demand for storage semiconductors due to the AI boom, indicating a potential "super cycle" in the industry [3] Gold Sector - Gold stocks have performed exceptionally well, with China Silver Group rising over 30% and Zijin Mining up more than 14%, attributed to international gold prices nearing $3,900 and a high probability of a Federal Reserve rate cut [3] - The combination of safe-haven demand and favorable policy conditions positions gold as a reliable investment for medium to long-term investors [3] Lithium Battery Sector - CATL's stock rose over 5%, reaching a new high, supported by increasing demand for lithium carbonate and a gradual decline in inventory levels, indicating a positive shift in the fundamentals [4] - The lithium battery sector is expected to benefit from seasonal demand in energy storage, reinforcing the notion of a stable investment environment [4] Innovative Pharmaceuticals - WuXi AppTec's stock increased by over 7%, with upcoming industry conferences and favorable policy changes providing optimism for growth in the innovative drug sector [4] - The sector is characterized by a gradual investment approach, aligning with the long-term strategy of monitoring key developments [4] Real Estate Sector - The real estate sector has faced challenges, with companies like China Overseas Land seeing a decline of over 4%, as reported profits for the first half of the year dropped by 27% [4] - The declining profit margins and adverse market conditions suggest that this sector may not be suitable for medium to long-term investment at this time [4] Investment Strategy - The current market dynamics reflect a logical rise and fall in stock prices, emphasizing the importance of understanding underlying industry fundamentals rather than short-term fluctuations [5] - Investors are encouraged to adopt a patient approach, focusing on long-term trends and opportunities within the market [5]

Market Overview - The Hong Kong stock market opened positively in October, with the Hang Seng Index closing at 27,287.12 points, up 431.56 points, a rise of 1.61% [2] - The Hang Seng Tech Index closed at 6,682.86 points, increasing by 217.20 points, a gain of 3.36% [4] Company Highlights - Alibaba Group (09988.HK) saw its stock rise over 4% during the day, closing at HKD 183.1, with a final increase of 3.45%. JPMorgan raised its target price for Alibaba's Hong Kong stock to HKD 240, indicating over 30% potential upside based on the current closing price [4] - JPMorgan reported that Alibaba Cloud's revenue growth has accelerated for eight consecutive quarters, with a year-on-year increase of 26% expected in Q2 2025, driven by demand in generative AI across various sectors [6] Sector Performance - The semiconductor sector experienced significant gains, with SMIC (00981.HK) surging 12% to reach a new historical high. Other notable performers included Longi Green Energy (06869.HK) up over 10%, and Huagong Technology (06908.HK) and Hua Hong Semiconductor (01347.HK) both rising over 7% [6] - The overall semiconductor industry is projected to continue its long-term growth, driven by AI data center demand and domestic substitution trends [8] Other Notable Stocks - The technology sector saw widespread gains, with Kuaishou-W (01024.HK) up over 8%, Baidu Group-SW (09888.HK) up over 4%, and JD Group-SW (09618.HK) and Xiaomi Group (01810.HK) both rising over 3% [8] - Gold stocks also performed well, with China Silver Group (00815.HK) increasing over 30% and Zijin Mining International (02259.HK) up over 14% [8] Industry Index Performance - The Wind Hong Kong secondary industry index showed significant increases in various sectors, with electrical equipment up 9.91%, non-ferrous metals up 5.29%, and hardware equipment up 4.70% [9]

Market Overview - The Hong Kong stock market opened positively in October, with the Hang Seng Index closing at 27,287.12 points, up 431.56 points, a rise of 1.61% [1] - The Hang Seng Tech Index closed at 6,682.86 points, increasing by 217.20 points, a gain of 3.36% [3] Company Highlights - Alibaba's stock (09988.HK) saw a peak increase of over 4% during the day, closing at HKD 183.1, with a final gain of 3.45% [3] - Morgan Stanley significantly raised Alibaba's target price for its Hong Kong shares to HKD 240, citing growth in cloud computing and e-commerce as key drivers for a higher valuation [3] - Based on the current closing price, Alibaba has over 30% upside potential according to Morgan Stanley's target price [3] Industry Insights - Morgan Stanley reported that Alibaba Cloud's revenue growth has accelerated for eight consecutive quarters, with a year-on-year increase of 26% expected in Q2 2025, driven by demand from generative AI in sectors like internet, autonomous driving, and embodied intelligence [5] - The report anticipates that the adoption of generative AI in China may outpace the previous SaaS wave, as it offers broader efficiency improvements and lower deployment barriers [5] - The semiconductor sector experienced a significant rally, with notable gains from companies like SMIC (00981.HK) up 12%, and other semiconductor firms also seeing increases of over 7% [5][7] Sector Performance - The semiconductor industry is expected to continue its long-term growth, driven by increased demand for storage from AI data centers and ongoing domestic substitution trends [7] - The technology sector saw widespread gains, with companies like Kuaishou (01024.HK) rising over 8%, and Baidu (09888.HK) increasing by over 4% [7] - The lithium battery sector also performed well, with CATL (03750.HK) hitting a new high with a rise of over 5% [7] Sector Index Performance - The top-performing sectors included electrical equipment (9.91%), non-ferrous metals (5.29%), and hardware equipment (4.70%) [8] - Conversely, sectors such as real estate II (-1.35%) and durable consumer goods (-4.14%) faced declines [8]